Epilepsy with Myoclonic-Atonic Seizures
Symptoms, Doctors, Treatments, Advances & More

Epilepsy with Myoclonic-Atonic Seizures Overview

Save information for later
Sign Up

Learn About Epilepsy with Myoclonic-Atonic Seizures

What is the definition of Epilepsy with Myoclonic-Atonic Seizures?
Epilepsy with myoclonic-atonic seizures is a rare epilepsy syndrome of early childhood. It is characterized by seizures of many different types, most often myoclonic-atonic, astatic, or generalized tonic-clonic seizures. Seizures can be followed by drop attacks, which can lead to falls and injuries. Absence seizures may occur. People with the condition may experience several seizures each day. The epilepsy may result in a delay or regression of skills. Autistic features and ataxic (poorly controlled) movements have been reported in some cases. Changes in the SCN1A, SCN1B, GABRG2, CHD2, and SLC6A1 genes can cause or contribute to Epilepsy with myoclonic-atonic seizures. However, in many cases the cause remains unknown. Epilepsy with myoclonic-atonic seizures can be inherited from an affected parent or occur for the first time in a family as a sporadic disease.
What are the alternative names for Epilepsy with Myoclonic-Atonic Seizures?
  • Epilepsy with myoclonic-atonic seizures
  • Doose syndrome
  • Epilepsy with myoclonic-astatic seizures
  • Epilepsy with myoclono-astatic crisis
  • Myoclonic astatic epilepsy
Who are the top Epilepsy with Myoclonic-Atonic Seizures Local Doctors?
Elite in Epilepsy with Myoclonic-Atonic Seizures
Elite in Epilepsy with Myoclonic-Atonic Seizures
Referral may be required

Werner K Doyle M.D. PC

223 E 34th St, 
New York, NY 
212-263-8870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Orrin Devinsky is a Neurologist practicing medicine in New York, New York. Dr. Devinsky is rated as an Elite provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Dravet Syndrome, Seizures, Epilepsy, and Deep Brain Stimulation.

Elite in Epilepsy with Myoclonic-Atonic Seizures
Elite in Epilepsy with Myoclonic-Atonic Seizures
Referral may be required

U Of M Neurology Clinic

1500 E Medical Center Dr, 
Ann Arbor, MI 
734-936-9020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jack Parent is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Parent is rated as an Elite provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, and Dravet Syndrome. Dr. Parent is board certified in Neurology and Clinical Neurophysiology. Dr. Parent is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Epilepsy with Myoclonic-Atonic Seizures
Distinguished in Epilepsy with Myoclonic-Atonic Seizures
Referral required

St. Vincent Neurosurgery

1041 North 29th Street, 
Billings, MT 
406-237-5577
Languages Spoken:
English, Spanish
See accepted insurances

Javier Echeverri is a Neurologist practicing medicine in Billings, Montana. Dr. Echeverri is rated as a Distinguished provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Essential Tremor, Parkinson's Disease, Movement Disorders, Epilepsy with Myoclonic-Atonic Seizures, and Deep Brain Stimulation.

View All Doctors
What are the latest Epilepsy with Myoclonic-Atonic Seizures Clinical Trials?
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients With Dravet Syndrome
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients With Dravet Syndrome
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Other
Study Phase: Phase 3

Summary: The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center